CelluTarget · Multifocal Motor Neuropathy · Clinical Trials
Phase 3
Active (not recruiting)
NCT04961567

Litifilimab (BIIB059)

Sponsored by Biogen ↗
View on ClinicalTrials.gov ↗
Timeline
Study Dates
Start Date
July 2021
Est. Completion
December 2026
Enrollment Target
400 participants
Status
Active (not recruiting)
Study Design
Primary Endpoint
Safety of litifilimab injections and whether they can improve symptoms of adults with SLE
Registry
ClinicalTrials.gov Record
Registry ID
NCT04961567
Direct Link
clinicaltrials.gov/NCT04961567 ↗
Related Treatment
Treatment Being Studied
Litifilimab (BIIB059) →